{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:33:51Z","timestamp":1794047631795,"version":"4.8.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s40265-015-0465-z","type":"journal-article","created":{"date-parts":[[2015,9,14]],"date-time":"2015-09-14T07:29:25Z","timestamp":1442215765000},"page":"1657-1668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Perampanel: A Review in Drug-Resistant Epilepsy"],"prefix":"10.1007","volume":"75","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,14]]},"reference":[{"issue":"12","key":"465_CR1","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40263-012-0021-2","volume":"26","author":"GL Plosker","year":"2012","unstructured":"Plosker GL. Perampanel: as adjunctive therapy in patients with partial-onset seizures. CNS Drugs. 2012;26(12):1085\u201396.","journal-title":"CNS Drugs."},{"key":"465_CR2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/JRLCR.S51475","volume":"7","author":"T Hanada","year":"2014","unstructured":"Hanada T. The AMPA receptor as a therapeutic target in epilepsy: preclinical and clinical evidence. J Receptor Ligand Channel Res. 2014;7:39\u201350.","journal-title":"J Receptor Ligand Channel Res."},{"issue":"10","key":"465_CR3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40263-013-0091-9","volume":"27","author":"WW Hsu","year":"2013","unstructured":"Hsu WW, Sing CW, He Y, et al. Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy. CNS Drugs. 2013;27(10):817\u201327.","journal-title":"CNS Drugs."},{"key":"465_CR4","doi-asserted-by":"crossref","unstructured":"Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 1981;22:489\u2013501.","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"issue":"1\u20132","key":"465_CR5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40120-013-0012-3","volume":"2","author":"DRM Ledingham","year":"2013","unstructured":"Ledingham DRM, Patsalos PN. Perampanel: what is its place in the management of partial onset epilepsy? Neurol Ther. 2013;2(1\u20132):13\u201324.","journal-title":"Neurol Ther."},{"issue":"2","key":"465_CR6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4103\/0972-2327.94988","volume":"15","author":"R Gursahani","year":"2012","unstructured":"Gursahani R, Gupta N. The adolescent or adult with generalized tonic-clonic seizures. Ann Indian Acad Neurol. 2012;15(2):81\u20138.","journal-title":"Ann Indian Acad Neurol."},{"issue":"10","key":"465_CR7","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1517\/14656566.2014.915029","volume":"15","author":"S Rheims","year":"2014","unstructured":"Rheims S, Ryvlin P. Pharmacotherapy for tonic-clonic seizures. Expert Opin Pharmacother. 2014;15(10):1417\u201326.","journal-title":"Expert Opin Pharmacother."},{"issue":"7","key":"465_CR8","first-page":"392","volume":"35","author":"MM Goldenberg","year":"2010","unstructured":"Goldenberg MM. Overview of drugs used for epilepsy and seizures. P T. 2010;35(7):392\u2013415.","journal-title":"P T."},{"key":"465_CR9","doi-asserted-by":"crossref","unstructured":"St. Louis EK, Rosenfeld WE, Bramley T. Antiepileptic drug monotherapy: the initial approach in epilepsy management. Curr Neuropharmacol. 2009;7(2):77\u201382.","DOI":"10.2174\/157015909788848866"},{"key":"465_CR10","unstructured":"National Institute for Health and Care Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. NICE guidelines [CG137]. 2012. http:\/\/www.nice.org.uk\/guidance\/cg137\/evidence . Accessed 19 May 2015."},{"issue":"4","key":"465_CR11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2014.891580","volume":"9","author":"T Hanada","year":"2014","unstructured":"Hanada T. The discovery and development of perampanel for the treatment of epilepsy. Expert Opin Drug Discov. 2014;9(4):449\u201358.","journal-title":"Expert Opin Drug Discov"},{"issue":"3","key":"465_CR12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/1756285615575696","volume":"8","author":"BJ Steinhoff","year":"2015","unstructured":"Steinhoff BJ. The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience. Ther Adv Neurol Disord. 2015;8(3):137\u201347.","journal-title":"Ther Adv Neurol Disord."},{"key":"465_CR13","unstructured":"Eisai Europe Ltd. Fycompa 2\u00a0mg, 4\u00a0mg, 6\u00a0mg, 8\u00a0mg, 10\u00a0mg, 12\u00a0mg film-coated tablets. EU summary of product characteristics. 2015. http:\/\/ec.europa.eu . Accessed 2 July 2015."},{"key":"465_CR14","unstructured":"Eisai Inc. FYCOMPA\u00ae (perampanel) tablets, for oral use. US prescribing information. 2015. https:\/\/www.fycompa.com . Accessed 2 July 2015."},{"issue":"Suppl 197","key":"465_CR15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ane.12100","volume":"127","author":"MA Rogawski","year":"2013","unstructured":"Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand. 2013;127(Suppl 197):19\u201324.","journal-title":"Acta Neurol Scand."},{"issue":"1","key":"465_CR16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12865","volume":"56","author":"PN Patsalos","year":"2015","unstructured":"Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015;56(1):12\u201327.","journal-title":"Epilepsia."},{"key":"465_CR17","unstructured":"Eisai Inc. A efficacy and safety study of adjunctive perampanel in primary generalized tonic clonic seizures [ClinicalTrials.gov identifier NCT01393743]. US National Institutes of Health, ClinicalTrials.gov [online]. 2014. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01393743 . Accessed 15 Apr 2015."},{"key":"465_CR18","unstructured":"French J, Krauss G, Wechsler R, et al. Adjunctive perampanel (PER) for treatment of drug-resistant primary generalized tonic-clonic (PGTC) seizures in patients (PTS) with idiopathic generalized epilepsy (IGE): a double-blind, randomized, placebo-controlled phase III trial (abstract 2.389 plus poster). In: 68th American Epilepsy Society Annual Meeting. 2014."},{"issue":"6","key":"465_CR19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","volume":"79","author":"JA French","year":"2012","unstructured":"French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79(6):589\u201396.","journal-title":"Neurology."},{"issue":"1","key":"465_CR20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","volume":"54","author":"JA French","year":"2013","unstructured":"French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54(1):117\u201325.","journal-title":"Epilepsia."},{"issue":"18","key":"465_CR21","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","volume":"78","author":"GL Krauss","year":"2012","unstructured":"Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78(18):1408\u201315.","journal-title":"Neurology."},{"issue":"8","key":"465_CR22","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","volume":"54","author":"BJ Steinhoff","year":"2013","unstructured":"Steinhoff BJ, Ben-Menachem E, Ryvlin P, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013;54(8):1481\u20139.","journal-title":"Epilepsia."},{"issue":"Suppl 1","key":"465_CR23","first-page":"64","volume":"22","author":"BJ Steinhoff","year":"2015","unstructured":"Steinhoff BJ, O\u2019Brien TJ, Yang H, et al. Efficacy of adjunctive perampanel in idiopathic generalised epilepsy patients with drug-resistant primary generalised tonic-clonic seizures by age, sex, race: a double-blind PBO-controlled phase 3 trial [abstract no. O2112]. Eur J Neurol. 2015;22(Suppl 1):64.","journal-title":"Eur J Neurol."},{"issue":"7","key":"465_CR24","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/epi.12643","volume":"55","author":"GL Krauss","year":"2014","unstructured":"Krauss GL, Perucca E, Ben-Menachem E, et al. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia. 2014;55(7):1058\u201368.","journal-title":"Epilepsia."},{"key":"465_CR25","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1212\/WNL.0000000000001558","volume":"84","author":"B Gidal","year":"2015","unstructured":"Gidal B, Laurenza A, Hussein Z, et al. Permapanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy. Neurology. 2015;84:1972\u201380.","journal-title":"Neurology."},{"key":"465_CR26","unstructured":"Tsong W, Hudgens S, Forsythe A, et al. Impact of adding perampanel to existing anti-epileptic drug (AED) therapy on health-related quality of life (HRQL) as measured by the quality of life in epilepsy inventory (QOLIE-31-P) in a pooled population of patients with partial-onset seizures (POS) from 3 phase III trials (abstract no. 3.301). In: 68th American Epilepsy Society Annual Meeting. 2014."},{"key":"465_CR27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ejpn.2015.02.008","volume":"19","author":"WE Rosenfeld","year":"2015","unstructured":"Rosenfeld WE, Conry J, Lagae L, et al. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study. Eur J Paediatr Neurol. 2015;19:435\u201345.","journal-title":"Eur J Paediatr Neurol."},{"key":"465_CR28","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.eplepsyres.2014.11.015","volume":"110","author":"I Leppik","year":"2015","unstructured":"Leppik I, Wechsler R, Williams B, et al. Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials. Epilepsy Res. 2015;110:216\u201320.","journal-title":"Epilepsy Res."},{"issue":"7","key":"465_CR29","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1111\/epi.13019","volume":"56","author":"B Vazquez","year":"2015","unstructured":"Vazquez B, Yang H, Williams B, et al. Perampanel efficacy and safety by gender: subanalysis of phase III randomized clinical studies in subjects with partial seizures. Epilepsia. 2015;56(7):e90\u20134.","journal-title":"Epilepsia."},{"issue":"3","key":"465_CR30","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/epi.12527","volume":"55","author":"LD Kramer","year":"2014","unstructured":"Kramer LD, Satlin A, Krauss GL, et al. Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies. Epilepsia. 2014;55(3):423\u201331.","journal-title":"Epilepsia."},{"issue":"4","key":"465_CR31","first-page":"263","volume":"126","author":"I Rektor","year":"2012","unstructured":"Rektor I, Krauss GL, Bar M, et al. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand. 2012;126(4):263\u20139.","journal-title":"Acta Neurol Scand."},{"key":"465_CR32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0404.2011.01588.x","volume":"125","author":"GL Krauss","year":"2012","unstructured":"Krauss GL, Bar M, Biton V, et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand. 2012;125:8\u201315.","journal-title":"Acta Neurol Scand."},{"key":"465_CR33","unstructured":"Data on file, Eisai, 2015."},{"issue":"8","key":"465_CR34","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/epi.12240","volume":"54","author":"BE Gidal","year":"2013","unstructured":"Gidal BE, Ferry J, Majid O. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Epilepsia. 2013;54(8):1490\u20137.","journal-title":"Epilepsia."},{"issue":"Suppl 1","key":"465_CR35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/epi.12504","volume":"55","author":"F Rugg-Gunn","year":"2014","unstructured":"Rugg-Gunn F. Adverse effects and safety profile of perampanel: a review of pooled data. Epilepsia. 2014;55(Suppl 1):13\u20135.","journal-title":"Epilepsia."},{"key":"465_CR36","doi-asserted-by":"crossref","unstructured":"Glauser T, Laurenza A, Yang H, et al. Efficacy and safety of adjunctive perampanel based on number of antiepileptic drugs at baseline [abstract no. P3.273]. Neurology. 82(10 Suppl).","DOI":"10.1212\/WNL.82.10_supplement.P3.273"},{"key":"465_CR37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.yebeh.2015.05.020","volume":"48","author":"D Ko","year":"2015","unstructured":"Ko D, Yang H, Williams B, et al. Perampanel in the treatment of partial seizures: time to onset and duration of most common adverse events from pooled phase III and extension studies. Epilepsy Behav. 2015;48:45\u201352.","journal-title":"Epilepsy Behav."},{"issue":"8","key":"465_CR38","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/epi.13054","volume":"56","author":"AB Ettinger","year":"2015","unstructured":"Ettinger AB, LoPresti A, Yang H, et al. Psychiatric and behavioural adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel. Epilepsia. 2015;56(8):1252\u201363.","journal-title":"Epilepsia."},{"key":"465_CR39","doi-asserted-by":"crossref","unstructured":"Leppik I, Yang H, Williams B, et al. Analysis of falls in epilepsy patients with partial onset seizures in perampanel phase 3 trials [abstract no. P3.272]. Neurology. 2014;82(10 Suppl).","DOI":"10.1212\/WNL.82.10_supplement.P3.272"},{"key":"465_CR40","unstructured":"Ettinger AB, Dobrinsky C, Yang H, et al. Review of suicidality events in perampanel clinical studies [poster no. 2.276]. In: 68th American Epilepsy Society Annual Meeting. 2014."},{"key":"465_CR41","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.eplepsyres.2015.04.010","volume":"114","author":"H Yang","year":"2015","unstructured":"Yang H, Laurenza A, Williams B, et al. Lack of effect of perampanel on QT interval duration: results from a thorough QT analysis and pooled partial seizure phase III clinical trials. Epilepsy Res. 2015;114:122\u201330.","journal-title":"Epilepsy Res."},{"issue":"Suppl 3","key":"465_CR42","first-page":"70","volume":"54","author":"A Laurenza","year":"2013","unstructured":"Laurenza A, Yang H, Squillacote D, et al. Adjunctive perampanel does not increase the risk of cardiac adverse events compared with placebo: a pooled analysis of three phase III trials [abstract no. P204]. Epilepsia. 2013;54(Suppl 3):70.","journal-title":"Epilepsia."},{"issue":"Suppl 1","key":"465_CR43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/epi.12494","volume":"55","author":"E Ben-Menachem","year":"2014","unstructured":"Ben-Menachem E. Medical management of refractory epilepsy\u2014practical treatment with novel antiepileptic drugs. Epilepsia. 2014;55(Suppl 1):3\u20138.","journal-title":"Epilepsia."},{"issue":"Suppl 194","key":"465_CR44","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/ane.12015","volume":"126","author":"E Trinka","year":"2012","unstructured":"Trinka E. Ideal characteristics of an antiepileptic drug: how do these impact treatment decisions for individual patients? Acta Neurol Scand. 2012;126(Suppl 194):10\u20138.","journal-title":"Acta Neurol Scand."},{"key":"465_CR45","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.WNL.0000123695.22623.32","volume":"62","author":"J French","year":"2004","unstructured":"French J, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;62:1261\u201373.","journal-title":"Neurology."},{"key":"465_CR46","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrd4126","volume":"12","author":"W Loscher","year":"2013","unstructured":"Loscher W, Klitgaard H, Twyman RE, et al. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov. 2013;12:757\u201376.","journal-title":"Nat Rev Drug Discov."},{"key":"465_CR47","unstructured":"Meador K, Yang H, Williams B, et al. Effect of adjunctive perampanel on cognition in adolescents with inadequately controlled partial-onset seizures [poster no. P4.344]. In: 66th American Academy of Neurology Annual Meeting. 2014."},{"issue":"6","key":"465_CR48","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1756285611417920","volume":"4","author":"CM Eddy","year":"2011","unstructured":"Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord. 2011;4(6):385\u2013407.","journal-title":"Ther Adv Neurol Disord."},{"key":"465_CR49","unstructured":"Thigpen J, Miller SE, Pond BB, et al. Behavioural side effects of antiepileptic drugs. US Pharm. 2013;38(11):HS15\u201320."},{"key":"465_CR50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/DHPS.S13070","volume":"3","author":"M Mula","year":"2011","unstructured":"Mula M, Hesdorffer DC. Suicidal behavior and antiepileptic drugs in epilepsy: analysis of the emerging evidence. Drug Health Patient Saf. 2011;3:15\u201320.","journal-title":"Drug Health Patient Saf."},{"issue":"6","key":"465_CR51","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/HRP.0000000000000039","volume":"22","author":"M Siamouli","year":"2014","unstructured":"Siamouli M, Samara M, Fountoulakis KN, et al. Is antiepileptic-induced suicidality a data-based class effect or an exaggeration? A comment on the literature. Harv Rev Psychiatry. 2014;22(6):379\u201381.","journal-title":"Harv Rev Psychiatry."},{"issue":"11","key":"465_CR52","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1111\/epi.12765","volume":"55","author":"C Hemery","year":"2014","unstructured":"Hemery C, Ryvlin P, Rheims S. Prevention of generalized tonic-clonic seizures in refractory focal epilepsy: a meta-analysis. Epilepsia. 2014;55(11):1789\u201399.","journal-title":"Epilepsia."},{"key":"465_CR53","unstructured":"Scottish Intercollegiate Guidelines Network. SIGN 143. Diagnosis and management of epilepsy in adults. A national clinical guideline. http:\/\/www.sign.ac.uk\/pdf\/SIGN143.pdf . Accessed 5 Aug 2015."},{"issue":"2","key":"465_CR54","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1055\/s-0035-1546276","volume":"46","author":"A Biro","year":"2015","unstructured":"Biro A, Stephani U, Tarallo T, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences. Neuropediatrics. 2015;46(2):110\u20136.","journal-title":"Neuropediatrics."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0465-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0465-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0465-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T03:12:03Z","timestamp":1718075523000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0465-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":54,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["465"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0465-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}